Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival Resea RCh Pa PeR Cancer Biology & Therapy 10:7, 728-735; October 1, 2010; © 2010 Landes Bioscience The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival 1 1 1, Matthew J. Wheater, Peter WM. Johnson and Jeremy P. Blaydes * s outhampton Cancer Research UK Centre; University of s outhampton s chool of Medicine; s outhampton General h ospital; UK Key words: breast cancer, eIF4E, phosphorylation, MAP kinase-interacting kinases, CGP57380, cyclin D1 Abbreviations: CGP57380, N3-(4-f luorophenyl)-1H-pyrazolo-[3,4-d]pyrimidine-3,4-diamine; ERα, oestrogen receptor alpha; peIF4E, eIF4E phosphorylated at serine 209; PR, progesterone receptor eIF4e is overexpressed in many tumors, including a high proportion of breast cancers. eIF4e is an oncogene, and signaling pathways which promote eIF4e activity represent potential targets for therapeutic intervention in cancer. MNKs phosphorylate eIF4e on serine 209, a modification that can be required for eIF4 e-dependent cell transformation. There is therefore a clear requirement to determine the role of MNKs in the proliferation and survival of cells from the major human tumors, such as breast cancer. Phosphorylated eIF4e protein was readily detectable in some breast tumor samples, but was below the limits of detection in others. Of six breast cancer cell lines representing the major sub- types of breast cancer, phosphorylated eIF4e was readily detectable in five of them, with MCF-7 cells displaying markedly lower levels. Long term colony forming assays demonstrated that all the five lines with high levels of phosphorylated eIF4e were highly sensitive to a MNK inhibitor. In short term assays, a range of responses was revealed. MCF-7 cells were insensitive in both assays. The anti-proliferative effects of the MNK inhibitor in breast cancer cells are primarily cytostatic, rather than cytotoxic, and are potentially due to the inhibition of cyclin D1 synthesis. Our data provide evidence that the sensitivity of breast cancer cells to MNK inhibition may correlate with baseline levels of eIF4e phosphorylation, and suggest that a proportion of breast cancers could be sensitive to inhibiting MNK kinase activity, and that the presence of phosphorylated eIF4e could provide a biomarker for the identification of responsive tumors. synthesis of a variety of proteins involved in cell growth, prolif- Introduction eration and invasion, including the cell cycle regulatory protein cyclin D1, Breast cancer represents a major health problem with over the transcription factor c-Myc, growth factors such 500,000 deaths annually world-wide. Substantial advances in the as VEGF and FGF2, as well as the anti-apoptotic protein MCL- 5 5-7 understanding of the biology underlying this disease have been 1. eIF4E acts as an oncogene in experimental models and is 8-12 made, and although the incidence continues to rise, mortality is overexpressed in a variety of human cancers. In breast can- falling in the western world. Despite this, in the face of meta- cer eIF4E overexpression correlates with cyclin D1, c-Myc and static disease, breast cancer remains almost universally fatal and, VEGF protein abundance, and is associated with poor outcome 14 15 although cure rates have improved in early stage disease, patients in node negative and node positive disease with a higher rate continue to relapse despite maximal therapy. of relapse. Low eIF4E protein following neoadjuvant therapy of Eukaryotic initiation factor 4E (eIF4E) has two distinct breast tumors has been associated with improved outcome. The activities in the cell; in the nucleus it associates with a subset mTOR signaling pathway, which promotes eIF4E activity, has of mRNAs that contain ‘4E-sensitivity elements’ within their already been validated as a therapeutic target in specific types of 3'UTRs and promotes their export through nuclear pores. In the cancer. Alternative strategies of targeting eIF4E are in develop- cytoplasm it binds the 5'-7-methylguanosine cap of mRNAs and ment, including small molecule inhibitors of the eIF4E-eIF4G recruits the eIF4F complex (eIF4G and eIF4A, an RNA helicase) interaction and anti-sense oligonucleotides targeted to eIF4E. to promote translation, particularly of mRNAs with complex Regulation of eIF4E activity forms a node of convergence of 1,2 5'-UTRs (e.g., containing inhibitory stem-loop structures). the PI3K/AKT and R AS/MAPK signaling pathways. Activated Through these two mechanisms eIF4E selectively enhances the AKT phosphorylates and inactivates TSC2 resulting in the *Correspondence to: Jeremy P. Blaydes; Email: [email protected] Submitted: 04/12/10; Revised: 07/12/10; Accepted: 07/12/10 Previously published online: www.landesbioscience.com/journals/cbt/article/12965 DOI: 10.4161/cbt.10.7.12965 728 Cancer Biology & Therapy Volume 10 Issue 7 Resea RCh Pa PeR Resea RCh Pa PeR effects of an inhibitor of MNK activity on proliferation and sur- vival signaling in a panel of breast cancer cell lines, including cells which are oestrogen receptor posi- tive, HER 2 overexpressing as well as an oestrogen receptor α (ERα), progesterone receptor (PR) and HER2 triple negative line. Results eIF4E phosphorylation in breast cancer tissues and cell lines. Using western blotting, we assessed cell lysates from 10 human breast tumor tissue samples for expres- sion of total eIF4E protein, as well as the abundance of the serine 209 phosphorylated form (peIF4E) (Fig. 1). Some samples in which eIF4E was readily detectable, also had higher amounts of the phos- phorylated protein (samples 3, 8–10). However other samples had measurable total eIF4E with barely detectable peIF4E (sam- ples 2, 4–7). The relative ratios of phosphorylated eIF4E to total eIF4E between the samples were Figure 1. eIF4e expression and phosphorylation in breast cancer tissue. equal protein concentrations from also calculated; these displayed a 10 breast cancer tissue samples were separated by s Ds -Pa Ge and western blots probed with antibodies to eIF4e and serine 209 phosphorylated eIF4e. Figure representative of two independent blots. Quantitation wide range which suggests clear shows the relative ratios of phosphorylated- to total eIF4e between the samples (*indicates total eIF4e is differences in MNK kinase activ- too low for a reliable analysis). ity between the tumors. We then proceeded to perform a compa- rable analysis of a panel of six Rheb-dependent activation of mTORC1. mTORC1 in turn breast cancer cell lines (Fig. 2) representing some of the main phosphorylates 4E-BP proteins, which reduces their ability to breast cancer subtypes (reviewed in ref. 28). MCF-7, ZR75.1 and inhibit eIF4E binding to eIF4G. ERK and p38 MAP kinases T47D have a luminal phenotype and express oestrogen recep- 18 +ve phosphorylate MNK1, leading to phosphorylation of eIF4E at tor α, BT474 and SKBr3 are HER2 and MDA-MB-231 has serine 209. This phosphorylation event can promote the eIF4E- a basal phenotype and is ERα, PR and HER2 negative. eIF4E 20 21 dependent export of mRNA such as cyclin D1, and MDM2; was present in all of the lines, though with variable abundance. its effects on eIF4E-dependent translation remain unclear. Phosphorylated eIF4E was, in most of the lines, more readily Critically, however, serine 209 phosphorylation is required for detectable than in the tumor samples, presumably because cell 5,20 the transforming and oncogenic effects of eIF4E. Furthermore lines were proliferating optimally in high concentrations of serum MNK kinases are dispensable for development and survival in growth factors. It was highest in the two HER2-expressing cell 23 +ve mammalian models making them potentially attractive as ther- lines, as well as the ERα line ZR75.1. Moderate levels were also +ve apeutic targets for cancer. seen in T47D (ERα ) as well as the MDA-MB-231 line which Inhibition of MNK kinase activity has shown antiprolif- harbours an activating k-RAS mutation. eIF4E phosphoryla- 24 25 erative effects in lung cancer and prostate cancer cell lines. tion was markedly lower in MCF-7 cells in this assay, consistent Approximately 25% of breast cancers are characterised by over- with our previous findings. expression of the HER2 receptor, which is associated with poor Time and dose-dependent inhibition of eIF4E phosphoryla- prognosis. HER2 promotes signaling through both the PI3K/ tion by CGP57380 in breast cancer cell lines. To investigate AKT and R AS/MAPK signaling pathways and MNK inhibition whether inhibition of eIF4E phosphorylation would have an has been shown to be antiproliferative in a single HER2 overex- effect on the proliferation of cell lines with higher basal levels pressing breast cancer cell line. Here we have investigated the of phosphorylated eIF4E we used a selective inhibitor of MNK www.landesbioscience.com Cancer Biology & Therapy 729 29,30 kinase activity, CGP57380. We initially per- formed dose-response analysis at a single time point (24 h exposure to the compound) to determine the optimum concentration required to inhibit eIF4E phosphorylation. For this the lines SkBr3 and BT474 were used, as they exhibited the high- est baseline phosphorylation at Ser209 (Fig. 3). In both cell lines there was a dose-dependent inhibi- tion of eIF4E-phosphorylation, with maximal inhi- bition at 20 µ M CGP57380, broadly consistent with findings from other investigators in different 29,30 experimental models. Of the other lines (data not shown), the dose response in ZR75.1 closely matched that seen in BT474 and, as we have pre- viously reported, 20 µ M CGP57380 also inhib- ited eIF4E phosphorylation in T47D cells. Time course analysis (Fig. 4) revealed some differences between the cell lines we examined. In BT474 cells, eIF4E phosphorylation was not detectable by the antibody after only 15 min exposure to CGP57380 and remained undetectable during 72 h continuous exposure to medium to which the compound had been added at the beginning of the experiment. The kinetics of inhibition were slightly slower in SKBr3 cells and phosphorylation could be detected again in the 72 h sample. MDA-MB-231 and T47D (not Figure 2. eIF4e expression and phosphorylation in breast cancer tissue. Cells in expo- nential growth phase were lysed 24 h after the application of fresh medium. Proteins shown) demonstrated similar kinetics of inhibi- were separated by s Ds -Pa Ge and western blots probed with antibodies to MNK1, tion to SKBr3 cells. The reasons for the differen- eIF4e and serine 209 phosphorylated eIF4e. Figure representative of two independent tial time courses of eIF4E phosphorylation can only blots. Quantitation is as per Figure 1. be speculated upon at present; differential rates of loss of phospho-eIF4E after addition of CGP57380 may indicate the activity of serine 209 phosphatases in some cell lines, though to our knowledge no such enzyme has yet been described. Differential rates of recovery of phosphorylation most likely reflect variations in the metabolism or export of the compound in different cell types, though the upregulation of a CGP57380-insensitive kinase is another possibility. Overall, the data demonstrate that eIF4E phosphorylated at serine 209 is either dephosphorylated or possibly degraded, in proliferating cells and MNK activity is continuously required to maintain eIF4E phosphorylation. Inhibition of breast cancer cell line proliferation by the MNK inhibitor CGP57380. Chrestensen et al. reported that basal phosphorylation of eIF4E was elevated in breast cancer cells that overexpress HER2, compared to those that did not. However their analysis of the effects of CGP57380 on cell proliferation was restricted to a single cell line, AU565. This line overexpresses HER2 and its proliferation in soft agar is CGP57380-sensitive. We therefore examined the effects of CGP57380 on the proliferation of each of the breast cancer cell lines in our panel. Long-term colony-forming assays were used as they provide a sensitive readout irrespective of whether any anti- proliferative effects are due to cell cycle inhibition or induction Figure 3. Dose response analysis of the inhibition of eIF4e phospho- rylation by CGP57380. BT474 and s KBr3 cells were treated with the of apoptosis (Fig. 5). CGP57380 had marked antiproliferative indicated concentrations of CGP57380 for 24 h prior to analysis of cell effects on both of the two HER2 overexpressing lines SKBr3 lysates by western blotting. and BT474, which exhibited high levels of phosphorylation of 730 Cancer Biology & Therapy Volume 10 Issue 7 in this assay were MCF-7, in which eIF4E phosphorylation is low or undetectable. Colony forming assays can be highly sensitive, as cells are assayed under conditions of stress induced by reduced survival signals from neighbouring cells. We therefore used an MTS cell viability assays to determine whether the anti-proliferative effects of CGP57380 were detectable in short term (72 h) assays of cells cultured at higher (40–95%) cell densities (Fig. 6). Moderate inhibition of proliferation was seen in the two HER 2 overexpressing cell lines, BT474 and SKBr3 and, to a lesser extent, MDA-MB-231 cells. MCF-7 cells were resistant to the compound, as they had been in the colony forming assays. T47D and ZR75.1 cells had shown a clear inhibitory response to CGP57380 in the colony forming assays, however in the MTS assays T47D showed no response and ZR75.1 appeared to show an increase in proliferation in response to the MNK inhibitor. This latter result needs interpreting with caution, as the MTS assay is only an indirect measure of cell viability; it determines the reductive capacity of poorly defined mitochondrial and cytoplasmic dehydrogenase enzymes. Thus an increase in the readout from this assay can be caused by, for example, a change in cellular metabolism that results in an increased cytoplasmic NADH:NAD ratio, rather than a genuine increase in cell pro- liferation. The apparent proliferative response in ZR75.1 cells was not observed using an assay which measures cellular DNA content (Cy QUA NT, Invitrogen) (data not shown). In summar y therefore, whilst all five cell lines that display moderate or high eIF4E phosphorylation are clearly responsive to CGP57380 in the sensitive colony forming assays, the two cell lines in which cell proliferation is known to be strictly dependent on signaling Figure 4. Time course analysis of the inhibition of eIF4e phosphoryla- from the HER2 receptor are the most responsive in short term tion by CGP57380. Cells were treated with 20 µ M CGP57380 for the cell viability assays, the line containing an activating k-RAS times as indicated. Proteins were analysed by western blotting. *, cross mutation being partially responsive. reacting band. Mechanism of inhibition of breast cancer cell proliferation by CGP57380. Live cell imag- ing was used to assess mitotic and apoptotic events in SKBr3 and MDA-MB-231 cells fol- lowing 24 h treatment with CGP57380 (Fig. 7). During the subsequent 24 h period, control SKBr3 cells underwent 33.3 ± 1.9 mitotic events per 100 cells present at the beginning of the imaging period. In the CGP57380-treated cul- tures, this was reduced to 13.4 ± 1.5 mitotic events per 100 initial cells. Apoptotic events were low in both control and treated samples, with 0.4 ± 0.3 and 2.1 ± 0.5 apoptotic events per 100 ini- Figure 5. eff ects of the MNK inhibitor, CGP57380, on colony formation by breast cancer tial cells in control and CGP57380 treated cells cell lines. Cells were treated with CGP57380 20 µ M or DMs O vehicle control for 24 h before respectively. Whilst this does represent a ≈5 fold being trypsinised, counted and re-plated at equal number in CGP57380 or DMs O. Colo- increase in the apoptotic rate, the overall con- nies were fixed with methanol and stained with Giemsa 9–12 days later. Representative of three replicate plates. tribution of apoptosis to the anti-proliferative effects of CGP57380 in SKBr3 cells is clearly minor compared to its more marked inhibitory eIF4E. Proliferation was also clearly inhibited in ZR75.1, T47D effect on cell cycle progression. Essentially the same effects on and MDA-MB-231 cells, which all had either high or moderate cell cycle progression were seen in MDA-MB-231 cells, although levels of eIF4E phosphorylation. The only breast cancer cell line in this cell line CGP57380 did not have any effect on the rate in which we did not observe substantial effects on proliferation of apoptosis. We also assessed the effects of CGP57380 on cell www.landesbioscience.com Cancer Biology & Therapy 731 Figure 6. eff ects of 72 h exposure to CGP57380 on breast cancer cell line proliferation. Cells for the experiment were plated at a density which resulted in them being in exponential growth phase at the point of assay. Data represents the results from three independent experiments for each cell line. (Bars = mean + se M, X axis labels represent CGP57380 concentration (µ M) 0 = 0.5% DMs O carrier control). cycle distribution using flow cytometry ( Fig. 8). Consistent with pro-apoptotic protein MCL-1 was unaffected throughout the 72 the live cell imaging data, MDA-MB-231 cells treated with h time course. CGP57380 accumulated in G phase, with decreased numbers of cells in S and G /M. Discussion To further investigate the mechanism of the effects of CGP57380 on proliferation we assessed the impact of CGP57380 We have shown that of a panel of six breast cancer cell lines rep- on known targets of phosphorylated eIF4E, i.e., cyclin D1 and resenting a spectrum of phenotypes, five show a reduction in pro - MCL-1. BT474 cells were analysed as they showed the most pro- liferation in response to an inhibitor of MNK kinase activity, found changes in eIF4E phosphorylation and proliferation in CGP57380. This confirms the findings of Chrestensen et al. response to the compound. CGP57380 reduced the abundance who demonstrated that the proliferation of a single HER2 over- of cyclin D1 to below detectable levels within 4 h of treatment expressing breast cancer line is inhibited by CGP57380, but also (Fig. 9). This is likely to be a cause of the inhibition of prolifera- extends this finding. Specifically, in the lines we have examined, tion induced by the compound. In contrast the abundance of the all those which demonstrated readily detectable baseline amounts 732 Cancer Biology & Therapy Volume 10 Issue 7 Figure 7. Live cell imaging analysis of CGP57380 treated breast cancer cells. MDa -MB-231 cells and s KBr3 cells were treated with CGP57380 20 µ M or DMs O vehicle control before under- going time lapse photomicroscopy. Graphs show the number of mitotic (black bars) and apoptotic events (white bars) per 100 initial cells during the 24 h imaging period. Results are mean of three experiments + se M. of phosphorylated eIF4E were sensitive to the compound. +ve These included both ERα lines as well as a HER2, ERα, PR negative line that harbours an activating k-R AS mutation. Importantly, no inhibition of proliferation was seen in the one cell line in which basal eIF4E phosphor- ylation was not readily detectable (MCF7). The breast tumor samples which we assessed showed considerable variation in the levels of eIF4E phosphorylation. Based on this, as well as the cell line data, it may therefore be that eIF4E phosphorylation could provide a biomarker for response to inhibition of the MNKs should this be developed as a therapeutic strategy in breast cancer. The restriction of anti-proliferative effects of CGP57380 to cell lines showing basal levels of phos- phorylated eIF4E is also an important finding when one considers the target specificity of the MNK inhibi - tor. It has been shown, at least in vitro, that CGP57380 is able to inhibit protein kinases in addition to the MNKs, raising the possibility that some of the effects of CGP57380 in cells could be through its effects on these enzymes. Suggested criteria for assessing the specificity of the effects of chemical inhibitors of protein function in cell regulation have recently been published. With respect to these criteria, we have determined (data not shown) that the effects of CGP57380 on cell proliferation occur in the same concentration range that inhibits eIF4E phosphorylation in the breast cancer cells. We also show a concordance between the presence of phosphorylated eIF4E in cells and their sensitivity to inhibition of proliferation by the compound. That MNKs are the relevant target of CGP57380 with respect to their anti- proliferative effects is further supported by downregulation of cyclin D1 and cell cycle arrest and being the dominant response to the inhibitor, the synthesis of cyclin D1 being known to be 20,34 increased by eIF4E phosphorylation. High expression of eIF4E has been established by several 14-16 groups to be a poor prognostic marker in breast cancer. Phosphorylated eIF4E can independently predict prognosis in lung cancer in a multivariate analysis of prognostic factors, and is also elevated in gastric and colorectal cancers. Thus the possibility of targeting MNK kinases in tumors in which overexpression of phosphorylated eIF4E is seen may well be considered as a novel therapeutic strategy worthy of further consideration. Figure 8. Cell cycle analysis of MDa -MB-231 cell line following CGP57380 Materials and Methods treatment. MDa -MB-231 cells were treated with CGP57380 20 µ M or DMs O (vehicle control); for 24 h prior to analysis of DNa content by propidium iodide staining and flow cytometry. Data shown is the means Culture of the panel of human breast cancer lines has been of three independently repeated experiments, each comprising three 37 described previously. Primary human breast cancer material replicates. s tudent’s t-test was used for statistical analysis. was obtained from the Southampton Cancer Research UK www.landesbioscience.com Cancer Biology & Therapy 733 Absorbance at 490 nm was measured after 2 h using a varioskan flash plate reader (Thermo Scientific). Mean of triplicate values from each of three experiments were combined for each cell line. For colony assays, cells were treated for 24 h before being trypsinised and counted. 1,250 cells were re-plated in medium containing CGP57380 or DMSO and incubated for 9–12 d before being fixed in methanol and stained with Giemsa stain (Sigma). For live cell imaging, cells were treated for 24 h before being imaged for 24 h using an Olympus IX81 microscope with CO and temperature controlled environmental chamber, con- trolled by SIS Cell P software. At least 30 cells per field were counted from three fields from each of three independent wells. Image J software was used for analysis. For cell cycle analy- sis, cells were treated for 24 h before being trypsinised with all washes retained and pelleted by centrifugation (1,000x g 4 min 4°C). Cells were washed in PBS and fixed with ethanol. Fixed cells were further washed in PBS and stained with propidium iodide (20 µ g/ml propidium iodide, 0.2 mg/ml R NAse A, 0.1% (v/v) Triton X-100 in PBS) for 30 min at room temperature. Flow cytometry was performed using a FACSCalibur (Becton Dickinson) and analysed with CellQuest software (Becton Dickinson). Proteins were analysed by immunoblotting as previously Figure 9. a bundance of MNK-regulated proteins in CGP57380-treated described. Images of blots were captured on a Bio-Rad Fluoro- BT474 cells. BT474 cells were treated with CGP57380 for times as indi- cated. Time 0 represents DMs O vehicle control. Protein expression was S-Max imager and quantified using Bio-Rad Quantity One determined by western blotting. software. The following antibodies were used: MNK1 #2196, eIF4E #9742, peIF4E (serine 209) #9741 (Cell Signalling tumor bank and assayed with local ethics committee approval. Technology), Cyclin D1 Ab-3 (Oncogene Research Products), The MNK 1 and 2 inhibitor N -(4-fluorophenyl)-1H-pyrazolo- MCl-1 sc-819 (Santa Cruz Biotechnology), actin (20-33) A5060 [3,4-d]pyrimidine-3,4-diamine (CGP57380, Tocris Bioscience) (Sigma). was used at concentrations as indicated, in dimethyl sulfoxide Acknowledgements vehicle to a final concentration of 0.5% (v/v) in culture medium. For proliferation assays, cells were plated to 96 well plates at We are grateful to Matthew Darley for technical support and the 1,000 cells/well with triplicate wells for each condition. 24 h Southampton School of Medicine Bioimaging Unit for assistance later CGP57380 was added at concentrations as indicated. After with live cell imaging. We thank Prof. Chris. Proud, University of 72 h MTS reagent (CellTitre Aqueous One Cell Proliferation Southampton, for helpful discussion. M.W. is supported by Cancer assay, Promega) was added as per the manufacturers instructions. Research UK. 8. Sorrells DL, Black DR, Meschonat C, Rhoads R, De 14. Flowers A, Chu QD, Panu L, Meschonat C, Caldito References Benedetti A, Gao M, et al. Detection of eIF4E gene G, Lowery-Nordberg M, et al. Eukaryotic initiation 1. Silva RL, Wendel HG MNK, EIF4E and targeting amplification in breast cancer by competitive PCR. factor 4E overexpression in triple-negative breast cancer translation for therapy. Cell Cycle 2008; 7:553-5. Ann Surg Oncol 1998; 5:232-7. predicts a worse outcome. Surgery 2009; 146:220-6. 2. Graff JR, Konicek BW, Carter JH, Marcusson EG. 9. Sorrells DL, Ghali GE, Meschonat C, DeFatta RJ, 15. McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson Targeting the eukaryotic translation initiation factor 4E Black D, Liu L, et al. Competitive PCR to detect eIF4E LW, Meschonat C, et al. A prospective trial on initia- for cancer therapy. Cancer Res 2008; 68:631-4. gene amplification in head and neck cancer. Head Neck tion factor 4E (eIF4E) overexpression and cancer recur- 3. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, 1999; 21:60-5. rence in node-positive breast cancer. Ann Surg 2005; Sonenberg N. Translation initiation of ornithine decar- 242:584-90. 10. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A. boxylase and nucleocytoplasmic transport of cyclin D1 Expression of the translation initiation factor eIF4E 16. Hiller DJ, Chu Q, Meschonat C, Panu L, Burton mRNA are increased in cells overexpressing eukaryotic in the polyp-cancer sequence in the colon. Cancer G, Li BD. Predictive value of eIF4E reduction after initiation factor 4E. Proc Natl Acad Sci USA 1996; Epidemiol Biomarkers Prev 2001; 10:663-6. neoadjuvant therapy in breast cancer. J Surg Res 2009; 93:1065-70. 156:265-9. 11. Matthews-Greer J, Caldito G, de Benedetti A, Herrera 4. De Benedetti A, Harris AL. eIF4E expression in GA, Dominguez-Malagon H, Chanona-Vilchis J, et 17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, tumors: its possible role in progression of malignancies. al. eIF4E as a marker for cervical neoplasia. Appl Kapoor A, et al. Temsirolimus, interferon alfa or both Int J Biochem Cell Biol 1999; 31:59-72. Immunohistochem Mol Morphol 2005; 13:367-70. for advanced renal-cell carcinoma. N Engl J Med 2007; 5. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, 356:2271-81. 12. Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen Ueda T, et al. Dissecting eIF4E action in tumorigenesis. LB. Overexpression of eukaryotic initiation factor 4E 18. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Genes Dev 2007; 21:3232-7. (eIF4E) and its clinical significance in lung adenocarci- Mitogen-activated protein kinases activate the serine/ 6. Lazaris-Karatzas A, Sonenberg N. The mRNA 5' cap- noma. Lung Cancer 2009; 66:237-44. threonine kinases Mnk1 and Mnk2. EMBO J 1997; binding protein, eIF-4E, cooperates with v-myc or E1A 16:1909-20. 13. Kleiner HE, Krishnan P, Tubbs J, Smith M, Meschonat in the transformation of primary rodent fibroblasts. C, Shi R, et al. Tissue microarray analysis of eIF4E 19. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Mol Cell Biol 1992; 12:1234-8. Kimball SR, Cooper JA. Phosphorylation of the cap- and its downstream effector proteins in human breast 7. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, cancer. J Exp Clin Cancer Res 2009; 28:5. binding protein eukaryotic translation initiation factor Sonenberg N. eIF4E—from translation to transforma- 4E by protein kinase Mnk1 in vivo. Mol Cell Biol tion. Oncogene 2004; 23:3172-9. 1999; 19:1871-80. 734 Cancer Biology & Therapy Volume 10 Issue 7 20. Topisirovic I, Ruiz-Gutierrez M, Borden KL. 26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich 33. Cohen P. Guidelines for the effective use of chemical Phosphorylation of the eukaryotic translation initiation A, McGuire WL. Human breast cancer: correlation of inhibitors of protein function to understand their roles factor eIF4E contributes to its transformation and mRNA relapse and survival with amplification of the HER-2/ in cell regulation. Biochemical Journal 2009; 425:53-4. transport activities. Cancer Res 2004; 64:8639-42. neu oncogene. Science 1987; 235:177-82. 34. Culjkovic B, Topisirovic I, Borden KL. Controlling 21. Phillips A, Blaydes JP. MNK1 and EIF4E are down- 27. Chrestensen CA, Shuman JK, Eschenroeder A, gene expression through RNA regulons: the role of stream effectors of MEKs in the regulation of the Worthington M, Gram H, Sturgill TW. MNK1 and the eukaryotic translation initiation factor eIF4E. Cell nuclear export of HDM2 mRNA. Oncogene 2008; MNK2 regulation in HER2-overexpressing breast can- Cycle 2007; 6:65-9. 27:1645-9. cer lines. J Biol Chem 2007; 282:4243-52. 35. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, 22. Buxade M, Parra-Palau JL, Proud CG. The Mnks: 28. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Hewitt SM, et al. Overexpression of phospho-eIF4E is MAP kinase-interacting kinases (MAP kinase signal- Wasielewski M, et al. Distinct gene mutation profiles associated with survival through AKT pathway in non- integrating kinases). Front Biosci 2008; 13:5359-73. among luminal-type and basal-type breast cancer cell small cell lung cancer. Clin Cancer Res 16:240-8. lines. Breast Cancer Res Treat 2009; 121:53-64. 23. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata 36. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun S, Fukunaga R. Mnk2 and Mnk1 are essential for con- 29. Knauf U, Tschopp C, Gram H. Negative regulation SY. Phosphorylated eukaryotic translation initiation stitutive and inducible phosphorylation of eukaryotic of protein translation by mitogen-activated protein factor 4 (eIF4E) is elevated in human cancer tissues. initiation factor 4E but not for cell growth or develop- kinase-interacting kinases 1 and 2. Mol Cell Biol 2001; Cancer Biol Ther 2009; 8:1463-9. ment. Mol Cell Biol 2004; 24:6539-49. 21:5500-11. 37. Phelps M, Darley M, Primrose JN, Blaydes JP. p53- 24. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe- 30. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez independent activation of the hdm2-P2 promoter Fukunaga R, et al. Inhibition of mammalian target R, Morrice N, et al. The Mnks are novel components through multiple transcription factor response elements of rapamycin induces phosphatidylinositol 3-kinase- in the control of TNFalpha biosynthesis and phos- results in elevated hdm2 expression in estrogen recep- dependent and Mnk-mediated eukaryotic translation phorylate and regulate hnRNP A1. Immunity 2005; tor alpha positive breast cancer cells. Cancer Res 2003; initiation factor 4E phosphorylation. Mol Cell Biol 23:177-89. 63:2616-23. 2007; 27:7405-13. 31. Dhanjaland P, Fry JR. Determinants of MTT reduction 25. Bianchini A, Loiarro M, Bielli P, Busa R, Paronetto MP, in rat hepatocytes. Biomarkers 1997; 2:111-6. Loreni F, et al. Phosphorylation of eIF4E by MNKs 32. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, supports protein synthesis, cell cycle progression and McLauchlan H, et al. The selectivity of protein proliferation in prostate cancer cells. Carcinogenesis kinase inhibitors: a further update. Biochem J 2007; 2008; 29:2279-88. 408:297-315. www.landesbioscience.com Cancer Biology & Therapy 735 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Biology & Therapy Taylor & Francis

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival

Download PDF
8 pages

Loading next page...
 
/lp/taylor-francis/the-role-of-mnk-proteins-and-eif4e-phosphorylation-in-breast-cancer-SB8qiULEfQ

References (37)

Publisher
Taylor & Francis
Copyright
Copyright © 2010 Landes Bioscience
ISSN
1555-8576
eISSN
1538-4047
DOI
10.4161/cbt.10.7.12965
pmid
20686366
Publisher site
See Article on Publisher Site

Abstract

Resea RCh Pa PeR Cancer Biology & Therapy 10:7, 728-735; October 1, 2010; © 2010 Landes Bioscience The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival 1 1 1, Matthew J. Wheater, Peter WM. Johnson and Jeremy P. Blaydes * s outhampton Cancer Research UK Centre; University of s outhampton s chool of Medicine; s outhampton General h ospital; UK Key words: breast cancer, eIF4E, phosphorylation, MAP kinase-interacting kinases, CGP57380, cyclin D1 Abbreviations: CGP57380, N3-(4-f luorophenyl)-1H-pyrazolo-[3,4-d]pyrimidine-3,4-diamine; ERα, oestrogen receptor alpha; peIF4E, eIF4E phosphorylated at serine 209; PR, progesterone receptor eIF4e is overexpressed in many tumors, including a high proportion of breast cancers. eIF4e is an oncogene, and signaling pathways which promote eIF4e activity represent potential targets for therapeutic intervention in cancer. MNKs phosphorylate eIF4e on serine 209, a modification that can be required for eIF4 e-dependent cell transformation. There is therefore a clear requirement to determine the role of MNKs in the proliferation and survival of cells from the major human tumors, such as breast cancer. Phosphorylated eIF4e protein was readily detectable in some breast tumor samples, but was below the limits of detection in others. Of six breast cancer cell lines representing the major sub- types of breast cancer, phosphorylated eIF4e was readily detectable in five of them, with MCF-7 cells displaying markedly lower levels. Long term colony forming assays demonstrated that all the five lines with high levels of phosphorylated eIF4e were highly sensitive to a MNK inhibitor. In short term assays, a range of responses was revealed. MCF-7 cells were insensitive in both assays. The anti-proliferative effects of the MNK inhibitor in breast cancer cells are primarily cytostatic, rather than cytotoxic, and are potentially due to the inhibition of cyclin D1 synthesis. Our data provide evidence that the sensitivity of breast cancer cells to MNK inhibition may correlate with baseline levels of eIF4e phosphorylation, and suggest that a proportion of breast cancers could be sensitive to inhibiting MNK kinase activity, and that the presence of phosphorylated eIF4e could provide a biomarker for the identification of responsive tumors. synthesis of a variety of proteins involved in cell growth, prolif- Introduction eration and invasion, including the cell cycle regulatory protein cyclin D1, Breast cancer represents a major health problem with over the transcription factor c-Myc, growth factors such 500,000 deaths annually world-wide. Substantial advances in the as VEGF and FGF2, as well as the anti-apoptotic protein MCL- 5 5-7 understanding of the biology underlying this disease have been 1. eIF4E acts as an oncogene in experimental models and is 8-12 made, and although the incidence continues to rise, mortality is overexpressed in a variety of human cancers. In breast can- falling in the western world. Despite this, in the face of meta- cer eIF4E overexpression correlates with cyclin D1, c-Myc and static disease, breast cancer remains almost universally fatal and, VEGF protein abundance, and is associated with poor outcome 14 15 although cure rates have improved in early stage disease, patients in node negative and node positive disease with a higher rate continue to relapse despite maximal therapy. of relapse. Low eIF4E protein following neoadjuvant therapy of Eukaryotic initiation factor 4E (eIF4E) has two distinct breast tumors has been associated with improved outcome. The activities in the cell; in the nucleus it associates with a subset mTOR signaling pathway, which promotes eIF4E activity, has of mRNAs that contain ‘4E-sensitivity elements’ within their already been validated as a therapeutic target in specific types of 3'UTRs and promotes their export through nuclear pores. In the cancer. Alternative strategies of targeting eIF4E are in develop- cytoplasm it binds the 5'-7-methylguanosine cap of mRNAs and ment, including small molecule inhibitors of the eIF4E-eIF4G recruits the eIF4F complex (eIF4G and eIF4A, an RNA helicase) interaction and anti-sense oligonucleotides targeted to eIF4E. to promote translation, particularly of mRNAs with complex Regulation of eIF4E activity forms a node of convergence of 1,2 5'-UTRs (e.g., containing inhibitory stem-loop structures). the PI3K/AKT and R AS/MAPK signaling pathways. Activated Through these two mechanisms eIF4E selectively enhances the AKT phosphorylates and inactivates TSC2 resulting in the *Correspondence to: Jeremy P. Blaydes; Email: [email protected] Submitted: 04/12/10; Revised: 07/12/10; Accepted: 07/12/10 Previously published online: www.landesbioscience.com/journals/cbt/article/12965 DOI: 10.4161/cbt.10.7.12965 728 Cancer Biology & Therapy Volume 10 Issue 7 Resea RCh Pa PeR Resea RCh Pa PeR effects of an inhibitor of MNK activity on proliferation and sur- vival signaling in a panel of breast cancer cell lines, including cells which are oestrogen receptor posi- tive, HER 2 overexpressing as well as an oestrogen receptor α (ERα), progesterone receptor (PR) and HER2 triple negative line. Results eIF4E phosphorylation in breast cancer tissues and cell lines. Using western blotting, we assessed cell lysates from 10 human breast tumor tissue samples for expres- sion of total eIF4E protein, as well as the abundance of the serine 209 phosphorylated form (peIF4E) (Fig. 1). Some samples in which eIF4E was readily detectable, also had higher amounts of the phos- phorylated protein (samples 3, 8–10). However other samples had measurable total eIF4E with barely detectable peIF4E (sam- ples 2, 4–7). The relative ratios of phosphorylated eIF4E to total eIF4E between the samples were Figure 1. eIF4e expression and phosphorylation in breast cancer tissue. equal protein concentrations from also calculated; these displayed a 10 breast cancer tissue samples were separated by s Ds -Pa Ge and western blots probed with antibodies to eIF4e and serine 209 phosphorylated eIF4e. Figure representative of two independent blots. Quantitation wide range which suggests clear shows the relative ratios of phosphorylated- to total eIF4e between the samples (*indicates total eIF4e is differences in MNK kinase activ- too low for a reliable analysis). ity between the tumors. We then proceeded to perform a compa- rable analysis of a panel of six Rheb-dependent activation of mTORC1. mTORC1 in turn breast cancer cell lines (Fig. 2) representing some of the main phosphorylates 4E-BP proteins, which reduces their ability to breast cancer subtypes (reviewed in ref. 28). MCF-7, ZR75.1 and inhibit eIF4E binding to eIF4G. ERK and p38 MAP kinases T47D have a luminal phenotype and express oestrogen recep- 18 +ve phosphorylate MNK1, leading to phosphorylation of eIF4E at tor α, BT474 and SKBr3 are HER2 and MDA-MB-231 has serine 209. This phosphorylation event can promote the eIF4E- a basal phenotype and is ERα, PR and HER2 negative. eIF4E 20 21 dependent export of mRNA such as cyclin D1, and MDM2; was present in all of the lines, though with variable abundance. its effects on eIF4E-dependent translation remain unclear. Phosphorylated eIF4E was, in most of the lines, more readily Critically, however, serine 209 phosphorylation is required for detectable than in the tumor samples, presumably because cell 5,20 the transforming and oncogenic effects of eIF4E. Furthermore lines were proliferating optimally in high concentrations of serum MNK kinases are dispensable for development and survival in growth factors. It was highest in the two HER2-expressing cell 23 +ve mammalian models making them potentially attractive as ther- lines, as well as the ERα line ZR75.1. Moderate levels were also +ve apeutic targets for cancer. seen in T47D (ERα ) as well as the MDA-MB-231 line which Inhibition of MNK kinase activity has shown antiprolif- harbours an activating k-RAS mutation. eIF4E phosphoryla- 24 25 erative effects in lung cancer and prostate cancer cell lines. tion was markedly lower in MCF-7 cells in this assay, consistent Approximately 25% of breast cancers are characterised by over- with our previous findings. expression of the HER2 receptor, which is associated with poor Time and dose-dependent inhibition of eIF4E phosphoryla- prognosis. HER2 promotes signaling through both the PI3K/ tion by CGP57380 in breast cancer cell lines. To investigate AKT and R AS/MAPK signaling pathways and MNK inhibition whether inhibition of eIF4E phosphorylation would have an has been shown to be antiproliferative in a single HER2 overex- effect on the proliferation of cell lines with higher basal levels pressing breast cancer cell line. Here we have investigated the of phosphorylated eIF4E we used a selective inhibitor of MNK www.landesbioscience.com Cancer Biology & Therapy 729 29,30 kinase activity, CGP57380. We initially per- formed dose-response analysis at a single time point (24 h exposure to the compound) to determine the optimum concentration required to inhibit eIF4E phosphorylation. For this the lines SkBr3 and BT474 were used, as they exhibited the high- est baseline phosphorylation at Ser209 (Fig. 3). In both cell lines there was a dose-dependent inhibi- tion of eIF4E-phosphorylation, with maximal inhi- bition at 20 µ M CGP57380, broadly consistent with findings from other investigators in different 29,30 experimental models. Of the other lines (data not shown), the dose response in ZR75.1 closely matched that seen in BT474 and, as we have pre- viously reported, 20 µ M CGP57380 also inhib- ited eIF4E phosphorylation in T47D cells. Time course analysis (Fig. 4) revealed some differences between the cell lines we examined. In BT474 cells, eIF4E phosphorylation was not detectable by the antibody after only 15 min exposure to CGP57380 and remained undetectable during 72 h continuous exposure to medium to which the compound had been added at the beginning of the experiment. The kinetics of inhibition were slightly slower in SKBr3 cells and phosphorylation could be detected again in the 72 h sample. MDA-MB-231 and T47D (not Figure 2. eIF4e expression and phosphorylation in breast cancer tissue. Cells in expo- nential growth phase were lysed 24 h after the application of fresh medium. Proteins shown) demonstrated similar kinetics of inhibi- were separated by s Ds -Pa Ge and western blots probed with antibodies to MNK1, tion to SKBr3 cells. The reasons for the differen- eIF4e and serine 209 phosphorylated eIF4e. Figure representative of two independent tial time courses of eIF4E phosphorylation can only blots. Quantitation is as per Figure 1. be speculated upon at present; differential rates of loss of phospho-eIF4E after addition of CGP57380 may indicate the activity of serine 209 phosphatases in some cell lines, though to our knowledge no such enzyme has yet been described. Differential rates of recovery of phosphorylation most likely reflect variations in the metabolism or export of the compound in different cell types, though the upregulation of a CGP57380-insensitive kinase is another possibility. Overall, the data demonstrate that eIF4E phosphorylated at serine 209 is either dephosphorylated or possibly degraded, in proliferating cells and MNK activity is continuously required to maintain eIF4E phosphorylation. Inhibition of breast cancer cell line proliferation by the MNK inhibitor CGP57380. Chrestensen et al. reported that basal phosphorylation of eIF4E was elevated in breast cancer cells that overexpress HER2, compared to those that did not. However their analysis of the effects of CGP57380 on cell proliferation was restricted to a single cell line, AU565. This line overexpresses HER2 and its proliferation in soft agar is CGP57380-sensitive. We therefore examined the effects of CGP57380 on the proliferation of each of the breast cancer cell lines in our panel. Long-term colony-forming assays were used as they provide a sensitive readout irrespective of whether any anti- proliferative effects are due to cell cycle inhibition or induction Figure 3. Dose response analysis of the inhibition of eIF4e phospho- rylation by CGP57380. BT474 and s KBr3 cells were treated with the of apoptosis (Fig. 5). CGP57380 had marked antiproliferative indicated concentrations of CGP57380 for 24 h prior to analysis of cell effects on both of the two HER2 overexpressing lines SKBr3 lysates by western blotting. and BT474, which exhibited high levels of phosphorylation of 730 Cancer Biology & Therapy Volume 10 Issue 7 in this assay were MCF-7, in which eIF4E phosphorylation is low or undetectable. Colony forming assays can be highly sensitive, as cells are assayed under conditions of stress induced by reduced survival signals from neighbouring cells. We therefore used an MTS cell viability assays to determine whether the anti-proliferative effects of CGP57380 were detectable in short term (72 h) assays of cells cultured at higher (40–95%) cell densities (Fig. 6). Moderate inhibition of proliferation was seen in the two HER 2 overexpressing cell lines, BT474 and SKBr3 and, to a lesser extent, MDA-MB-231 cells. MCF-7 cells were resistant to the compound, as they had been in the colony forming assays. T47D and ZR75.1 cells had shown a clear inhibitory response to CGP57380 in the colony forming assays, however in the MTS assays T47D showed no response and ZR75.1 appeared to show an increase in proliferation in response to the MNK inhibitor. This latter result needs interpreting with caution, as the MTS assay is only an indirect measure of cell viability; it determines the reductive capacity of poorly defined mitochondrial and cytoplasmic dehydrogenase enzymes. Thus an increase in the readout from this assay can be caused by, for example, a change in cellular metabolism that results in an increased cytoplasmic NADH:NAD ratio, rather than a genuine increase in cell pro- liferation. The apparent proliferative response in ZR75.1 cells was not observed using an assay which measures cellular DNA content (Cy QUA NT, Invitrogen) (data not shown). In summar y therefore, whilst all five cell lines that display moderate or high eIF4E phosphorylation are clearly responsive to CGP57380 in the sensitive colony forming assays, the two cell lines in which cell proliferation is known to be strictly dependent on signaling Figure 4. Time course analysis of the inhibition of eIF4e phosphoryla- from the HER2 receptor are the most responsive in short term tion by CGP57380. Cells were treated with 20 µ M CGP57380 for the cell viability assays, the line containing an activating k-RAS times as indicated. Proteins were analysed by western blotting. *, cross mutation being partially responsive. reacting band. Mechanism of inhibition of breast cancer cell proliferation by CGP57380. Live cell imag- ing was used to assess mitotic and apoptotic events in SKBr3 and MDA-MB-231 cells fol- lowing 24 h treatment with CGP57380 (Fig. 7). During the subsequent 24 h period, control SKBr3 cells underwent 33.3 ± 1.9 mitotic events per 100 cells present at the beginning of the imaging period. In the CGP57380-treated cul- tures, this was reduced to 13.4 ± 1.5 mitotic events per 100 initial cells. Apoptotic events were low in both control and treated samples, with 0.4 ± 0.3 and 2.1 ± 0.5 apoptotic events per 100 ini- Figure 5. eff ects of the MNK inhibitor, CGP57380, on colony formation by breast cancer tial cells in control and CGP57380 treated cells cell lines. Cells were treated with CGP57380 20 µ M or DMs O vehicle control for 24 h before respectively. Whilst this does represent a ≈5 fold being trypsinised, counted and re-plated at equal number in CGP57380 or DMs O. Colo- increase in the apoptotic rate, the overall con- nies were fixed with methanol and stained with Giemsa 9–12 days later. Representative of three replicate plates. tribution of apoptosis to the anti-proliferative effects of CGP57380 in SKBr3 cells is clearly minor compared to its more marked inhibitory eIF4E. Proliferation was also clearly inhibited in ZR75.1, T47D effect on cell cycle progression. Essentially the same effects on and MDA-MB-231 cells, which all had either high or moderate cell cycle progression were seen in MDA-MB-231 cells, although levels of eIF4E phosphorylation. The only breast cancer cell line in this cell line CGP57380 did not have any effect on the rate in which we did not observe substantial effects on proliferation of apoptosis. We also assessed the effects of CGP57380 on cell www.landesbioscience.com Cancer Biology & Therapy 731 Figure 6. eff ects of 72 h exposure to CGP57380 on breast cancer cell line proliferation. Cells for the experiment were plated at a density which resulted in them being in exponential growth phase at the point of assay. Data represents the results from three independent experiments for each cell line. (Bars = mean + se M, X axis labels represent CGP57380 concentration (µ M) 0 = 0.5% DMs O carrier control). cycle distribution using flow cytometry ( Fig. 8). Consistent with pro-apoptotic protein MCL-1 was unaffected throughout the 72 the live cell imaging data, MDA-MB-231 cells treated with h time course. CGP57380 accumulated in G phase, with decreased numbers of cells in S and G /M. Discussion To further investigate the mechanism of the effects of CGP57380 on proliferation we assessed the impact of CGP57380 We have shown that of a panel of six breast cancer cell lines rep- on known targets of phosphorylated eIF4E, i.e., cyclin D1 and resenting a spectrum of phenotypes, five show a reduction in pro - MCL-1. BT474 cells were analysed as they showed the most pro- liferation in response to an inhibitor of MNK kinase activity, found changes in eIF4E phosphorylation and proliferation in CGP57380. This confirms the findings of Chrestensen et al. response to the compound. CGP57380 reduced the abundance who demonstrated that the proliferation of a single HER2 over- of cyclin D1 to below detectable levels within 4 h of treatment expressing breast cancer line is inhibited by CGP57380, but also (Fig. 9). This is likely to be a cause of the inhibition of prolifera- extends this finding. Specifically, in the lines we have examined, tion induced by the compound. In contrast the abundance of the all those which demonstrated readily detectable baseline amounts 732 Cancer Biology & Therapy Volume 10 Issue 7 Figure 7. Live cell imaging analysis of CGP57380 treated breast cancer cells. MDa -MB-231 cells and s KBr3 cells were treated with CGP57380 20 µ M or DMs O vehicle control before under- going time lapse photomicroscopy. Graphs show the number of mitotic (black bars) and apoptotic events (white bars) per 100 initial cells during the 24 h imaging period. Results are mean of three experiments + se M. of phosphorylated eIF4E were sensitive to the compound. +ve These included both ERα lines as well as a HER2, ERα, PR negative line that harbours an activating k-R AS mutation. Importantly, no inhibition of proliferation was seen in the one cell line in which basal eIF4E phosphor- ylation was not readily detectable (MCF7). The breast tumor samples which we assessed showed considerable variation in the levels of eIF4E phosphorylation. Based on this, as well as the cell line data, it may therefore be that eIF4E phosphorylation could provide a biomarker for response to inhibition of the MNKs should this be developed as a therapeutic strategy in breast cancer. The restriction of anti-proliferative effects of CGP57380 to cell lines showing basal levels of phos- phorylated eIF4E is also an important finding when one considers the target specificity of the MNK inhibi - tor. It has been shown, at least in vitro, that CGP57380 is able to inhibit protein kinases in addition to the MNKs, raising the possibility that some of the effects of CGP57380 in cells could be through its effects on these enzymes. Suggested criteria for assessing the specificity of the effects of chemical inhibitors of protein function in cell regulation have recently been published. With respect to these criteria, we have determined (data not shown) that the effects of CGP57380 on cell proliferation occur in the same concentration range that inhibits eIF4E phosphorylation in the breast cancer cells. We also show a concordance between the presence of phosphorylated eIF4E in cells and their sensitivity to inhibition of proliferation by the compound. That MNKs are the relevant target of CGP57380 with respect to their anti- proliferative effects is further supported by downregulation of cyclin D1 and cell cycle arrest and being the dominant response to the inhibitor, the synthesis of cyclin D1 being known to be 20,34 increased by eIF4E phosphorylation. High expression of eIF4E has been established by several 14-16 groups to be a poor prognostic marker in breast cancer. Phosphorylated eIF4E can independently predict prognosis in lung cancer in a multivariate analysis of prognostic factors, and is also elevated in gastric and colorectal cancers. Thus the possibility of targeting MNK kinases in tumors in which overexpression of phosphorylated eIF4E is seen may well be considered as a novel therapeutic strategy worthy of further consideration. Figure 8. Cell cycle analysis of MDa -MB-231 cell line following CGP57380 Materials and Methods treatment. MDa -MB-231 cells were treated with CGP57380 20 µ M or DMs O (vehicle control); for 24 h prior to analysis of DNa content by propidium iodide staining and flow cytometry. Data shown is the means Culture of the panel of human breast cancer lines has been of three independently repeated experiments, each comprising three 37 described previously. Primary human breast cancer material replicates. s tudent’s t-test was used for statistical analysis. was obtained from the Southampton Cancer Research UK www.landesbioscience.com Cancer Biology & Therapy 733 Absorbance at 490 nm was measured after 2 h using a varioskan flash plate reader (Thermo Scientific). Mean of triplicate values from each of three experiments were combined for each cell line. For colony assays, cells were treated for 24 h before being trypsinised and counted. 1,250 cells were re-plated in medium containing CGP57380 or DMSO and incubated for 9–12 d before being fixed in methanol and stained with Giemsa stain (Sigma). For live cell imaging, cells were treated for 24 h before being imaged for 24 h using an Olympus IX81 microscope with CO and temperature controlled environmental chamber, con- trolled by SIS Cell P software. At least 30 cells per field were counted from three fields from each of three independent wells. Image J software was used for analysis. For cell cycle analy- sis, cells were treated for 24 h before being trypsinised with all washes retained and pelleted by centrifugation (1,000x g 4 min 4°C). Cells were washed in PBS and fixed with ethanol. Fixed cells were further washed in PBS and stained with propidium iodide (20 µ g/ml propidium iodide, 0.2 mg/ml R NAse A, 0.1% (v/v) Triton X-100 in PBS) for 30 min at room temperature. Flow cytometry was performed using a FACSCalibur (Becton Dickinson) and analysed with CellQuest software (Becton Dickinson). Proteins were analysed by immunoblotting as previously Figure 9. a bundance of MNK-regulated proteins in CGP57380-treated described. Images of blots were captured on a Bio-Rad Fluoro- BT474 cells. BT474 cells were treated with CGP57380 for times as indi- cated. Time 0 represents DMs O vehicle control. Protein expression was S-Max imager and quantified using Bio-Rad Quantity One determined by western blotting. software. The following antibodies were used: MNK1 #2196, eIF4E #9742, peIF4E (serine 209) #9741 (Cell Signalling tumor bank and assayed with local ethics committee approval. Technology), Cyclin D1 Ab-3 (Oncogene Research Products), The MNK 1 and 2 inhibitor N -(4-fluorophenyl)-1H-pyrazolo- MCl-1 sc-819 (Santa Cruz Biotechnology), actin (20-33) A5060 [3,4-d]pyrimidine-3,4-diamine (CGP57380, Tocris Bioscience) (Sigma). was used at concentrations as indicated, in dimethyl sulfoxide Acknowledgements vehicle to a final concentration of 0.5% (v/v) in culture medium. For proliferation assays, cells were plated to 96 well plates at We are grateful to Matthew Darley for technical support and the 1,000 cells/well with triplicate wells for each condition. 24 h Southampton School of Medicine Bioimaging Unit for assistance later CGP57380 was added at concentrations as indicated. After with live cell imaging. We thank Prof. Chris. Proud, University of 72 h MTS reagent (CellTitre Aqueous One Cell Proliferation Southampton, for helpful discussion. M.W. is supported by Cancer assay, Promega) was added as per the manufacturers instructions. Research UK. 8. Sorrells DL, Black DR, Meschonat C, Rhoads R, De 14. Flowers A, Chu QD, Panu L, Meschonat C, Caldito References Benedetti A, Gao M, et al. Detection of eIF4E gene G, Lowery-Nordberg M, et al. Eukaryotic initiation 1. Silva RL, Wendel HG MNK, EIF4E and targeting amplification in breast cancer by competitive PCR. factor 4E overexpression in triple-negative breast cancer translation for therapy. Cell Cycle 2008; 7:553-5. Ann Surg Oncol 1998; 5:232-7. predicts a worse outcome. Surgery 2009; 146:220-6. 2. Graff JR, Konicek BW, Carter JH, Marcusson EG. 9. Sorrells DL, Ghali GE, Meschonat C, DeFatta RJ, 15. McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson Targeting the eukaryotic translation initiation factor 4E Black D, Liu L, et al. Competitive PCR to detect eIF4E LW, Meschonat C, et al. A prospective trial on initia- for cancer therapy. Cancer Res 2008; 68:631-4. gene amplification in head and neck cancer. Head Neck tion factor 4E (eIF4E) overexpression and cancer recur- 3. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, 1999; 21:60-5. rence in node-positive breast cancer. Ann Surg 2005; Sonenberg N. Translation initiation of ornithine decar- 242:584-90. 10. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A. boxylase and nucleocytoplasmic transport of cyclin D1 Expression of the translation initiation factor eIF4E 16. Hiller DJ, Chu Q, Meschonat C, Panu L, Burton mRNA are increased in cells overexpressing eukaryotic in the polyp-cancer sequence in the colon. Cancer G, Li BD. Predictive value of eIF4E reduction after initiation factor 4E. Proc Natl Acad Sci USA 1996; Epidemiol Biomarkers Prev 2001; 10:663-6. neoadjuvant therapy in breast cancer. J Surg Res 2009; 93:1065-70. 156:265-9. 11. Matthews-Greer J, Caldito G, de Benedetti A, Herrera 4. De Benedetti A, Harris AL. eIF4E expression in GA, Dominguez-Malagon H, Chanona-Vilchis J, et 17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, tumors: its possible role in progression of malignancies. al. eIF4E as a marker for cervical neoplasia. Appl Kapoor A, et al. Temsirolimus, interferon alfa or both Int J Biochem Cell Biol 1999; 31:59-72. Immunohistochem Mol Morphol 2005; 13:367-70. for advanced renal-cell carcinoma. N Engl J Med 2007; 5. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, 356:2271-81. 12. Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen Ueda T, et al. Dissecting eIF4E action in tumorigenesis. LB. Overexpression of eukaryotic initiation factor 4E 18. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Genes Dev 2007; 21:3232-7. (eIF4E) and its clinical significance in lung adenocarci- Mitogen-activated protein kinases activate the serine/ 6. Lazaris-Karatzas A, Sonenberg N. The mRNA 5' cap- noma. Lung Cancer 2009; 66:237-44. threonine kinases Mnk1 and Mnk2. EMBO J 1997; binding protein, eIF-4E, cooperates with v-myc or E1A 16:1909-20. 13. Kleiner HE, Krishnan P, Tubbs J, Smith M, Meschonat in the transformation of primary rodent fibroblasts. C, Shi R, et al. Tissue microarray analysis of eIF4E 19. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Mol Cell Biol 1992; 12:1234-8. Kimball SR, Cooper JA. Phosphorylation of the cap- and its downstream effector proteins in human breast 7. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, cancer. J Exp Clin Cancer Res 2009; 28:5. binding protein eukaryotic translation initiation factor Sonenberg N. eIF4E—from translation to transforma- 4E by protein kinase Mnk1 in vivo. Mol Cell Biol tion. Oncogene 2004; 23:3172-9. 1999; 19:1871-80. 734 Cancer Biology & Therapy Volume 10 Issue 7 20. Topisirovic I, Ruiz-Gutierrez M, Borden KL. 26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich 33. Cohen P. Guidelines for the effective use of chemical Phosphorylation of the eukaryotic translation initiation A, McGuire WL. Human breast cancer: correlation of inhibitors of protein function to understand their roles factor eIF4E contributes to its transformation and mRNA relapse and survival with amplification of the HER-2/ in cell regulation. Biochemical Journal 2009; 425:53-4. transport activities. Cancer Res 2004; 64:8639-42. neu oncogene. Science 1987; 235:177-82. 34. Culjkovic B, Topisirovic I, Borden KL. Controlling 21. Phillips A, Blaydes JP. MNK1 and EIF4E are down- 27. Chrestensen CA, Shuman JK, Eschenroeder A, gene expression through RNA regulons: the role of stream effectors of MEKs in the regulation of the Worthington M, Gram H, Sturgill TW. MNK1 and the eukaryotic translation initiation factor eIF4E. Cell nuclear export of HDM2 mRNA. Oncogene 2008; MNK2 regulation in HER2-overexpressing breast can- Cycle 2007; 6:65-9. 27:1645-9. cer lines. J Biol Chem 2007; 282:4243-52. 35. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, 22. Buxade M, Parra-Palau JL, Proud CG. The Mnks: 28. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Hewitt SM, et al. Overexpression of phospho-eIF4E is MAP kinase-interacting kinases (MAP kinase signal- Wasielewski M, et al. Distinct gene mutation profiles associated with survival through AKT pathway in non- integrating kinases). Front Biosci 2008; 13:5359-73. among luminal-type and basal-type breast cancer cell small cell lung cancer. Clin Cancer Res 16:240-8. lines. Breast Cancer Res Treat 2009; 121:53-64. 23. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata 36. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun S, Fukunaga R. Mnk2 and Mnk1 are essential for con- 29. Knauf U, Tschopp C, Gram H. Negative regulation SY. Phosphorylated eukaryotic translation initiation stitutive and inducible phosphorylation of eukaryotic of protein translation by mitogen-activated protein factor 4 (eIF4E) is elevated in human cancer tissues. initiation factor 4E but not for cell growth or develop- kinase-interacting kinases 1 and 2. Mol Cell Biol 2001; Cancer Biol Ther 2009; 8:1463-9. ment. Mol Cell Biol 2004; 24:6539-49. 21:5500-11. 37. Phelps M, Darley M, Primrose JN, Blaydes JP. p53- 24. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe- 30. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez independent activation of the hdm2-P2 promoter Fukunaga R, et al. Inhibition of mammalian target R, Morrice N, et al. The Mnks are novel components through multiple transcription factor response elements of rapamycin induces phosphatidylinositol 3-kinase- in the control of TNFalpha biosynthesis and phos- results in elevated hdm2 expression in estrogen recep- dependent and Mnk-mediated eukaryotic translation phorylate and regulate hnRNP A1. Immunity 2005; tor alpha positive breast cancer cells. Cancer Res 2003; initiation factor 4E phosphorylation. Mol Cell Biol 23:177-89. 63:2616-23. 2007; 27:7405-13. 31. Dhanjaland P, Fry JR. Determinants of MTT reduction 25. Bianchini A, Loiarro M, Bielli P, Busa R, Paronetto MP, in rat hepatocytes. Biomarkers 1997; 2:111-6. Loreni F, et al. Phosphorylation of eIF4E by MNKs 32. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, supports protein synthesis, cell cycle progression and McLauchlan H, et al. The selectivity of protein proliferation in prostate cancer cells. Carcinogenesis kinase inhibitors: a further update. Biochem J 2007; 2008; 29:2279-88. 408:297-315. www.landesbioscience.com Cancer Biology & Therapy 735

Journal

Cancer Biology & Therapy – Taylor & Francis

Published: Oct 1, 2010

There are no references for this article.